Project Grant R43CA246788

This Project Grant award of $728,000.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by St. Jude Children's Research Hospital Inc. on XPO1 as a therapeutic target in ZFTA-RELA-driven ependymoma. The two-year award, running from September 1, 2023 to August 31, 2025, will fund medical research to investigate XPO1 as a potential treatment for this rare pediatric brain cancer. The research focuses on...

Federal Grant Award Summary Seattle Children's Research Institute received a $434,361 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025 through August 31, 2027. The project focuses on developing a multispecific T cell engaging (MTE) therapy targeting mixed-phenotype acute leukemia (MPAL), a high-risk leukemia subtype that presents with both myeloid and lymphoid surface antigens. The research aims...

This $683,472 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Cincinnati to develop a novel targeted therapy for acute myeloid leukemia (AML). The key objectives are to therapeutically target the DHODH enzyme to induce AML cell differentiation, activate the immune system, and induce ferroptosis-mediated cell death. This approach aims to better differentiate AML cells from normal hematopoietic stem cells and enhance...

The Department of the Army Medical Command awarded a $694,200 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) to support research developing a novel therapeutic target in XP11.2 translocation renal cell carcinoma. The grant was awarded on July 1, 2022 under the Military Medical Research and Development program (CFDA 12.420), with a completion date of June 30, 2025. Through this funding, Dfci will conduct research to investigate medical solutions for renal cell...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $708,100 Project Grant to the Dana-Farber Cancer Institute, Inc. (Dfci) to conduct research on "Overcoming Rebound Growth of Pediatric Low-Grade Glioas Following MAPK Pathway Inhibition." The grant, which runs from July 1, 2024 to June 30, 2026, will support Dfci's efforts to better understand the mechanisms driving recurrence of pediatric low-grade glioma brain tumors after...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

The Department of the Army Medical Command awarded a $884,997 Project Grant to the Dana-Farber Cancer Institute, Inc. (doing business as Dfci) under the Military Medical Research and Development program. The three-year grant will fund research to intervene in the TP53 pathway phosphatome in pediatric high-grade gliomas. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical research that investigates medical solutions...

The National Cancer Institute (NCI) awarded a $483,110 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Beckman Research Institute of the City of Hope to conduct research on the functional role of PAX5 mutations in B-cell acute lymphoblastic leukemia (B-ALL). The 5-year project aims to systematically dissect the mechanisms by which PAX5 mutations, which occur in over 10% of B-ALL cases, contribute to disease initiation and progression. The research will use orthogonal...

The Department of the Army Medical Command awarded a $2,247,531 project grant to The Children's Hospital of Philadelphia through the Military Medical Research and Development program (CFDA 12.420) to conduct a comprehensive evaluation of immune function in patients receiving multimodal therapy for high-risk neuroblastoma. The four-year project beginning September 1, 2022 will apply basic, applied, and advanced biomedical research approaches to transform pediatric cancer care and investigate...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $560,458 to Childrens Mercy Hospital in Missouri to support research that aims to identify novel compounds and strategies for inducing cell death specifically in cancer cells deficient in the p53 tumor suppressor gene. The key objective is to develop an efficient approach to trigger "p53 synthetic lethality", a concept where cancer cells with p53...